Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ADTX 
Aditxt Inc. (ADTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: ADTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $61
1 Year Target Price $61
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.03M USD | Price to earnings Ratio - | 1Y Target Price 61 |
Price to earnings Ratio - | 1Y Target Price 61 | ||
Volume (30-day avg) 1 | Beta 1.41 | 52 Weeks Range 0.81 - 4670.00 | Updated Date 09/15/2025 |
52 Weeks Range 0.81 - 4670.00 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2942.24 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -612788.4% |
Management Effectiveness
Return on Assets (TTM) -45.26% | Return on Equity (TTM) -282.21% |
Valuation
Trailing PE - | Forward PE 0.37 | Enterprise Value 10185110 | Price to Sales(TTM) 417.09 |
Enterprise Value 10185110 | Price to Sales(TTM) 417.09 | ||
Enterprise Value to Revenue 845.17 | Enterprise Value to EBITDA 0.02 | Shares Outstanding 4976560 | Shares Floating 4976555 |
Shares Outstanding 4976560 | Shares Floating 4976555 | ||
Percent Insiders - | Percent Institutions 0.79 |
Upturn AI SWOT
Aditxt Inc.
Company Overview
History and Background
Aditxt, Inc. was founded in 2017 and focuses on developing technologies for immune system monitoring and modulation. It has gone through several strategic shifts, focusing on different aspects of the immune system and related technologies.
Core Business Areas
- AditxtScore: Personalized immune profiling that measures individual immune response, allowing patients to have personalized immunosuppressant regimens to reduce the incidence of transplant rejection or autoimmune disorders.
- AditxtReprogramming: Technologies to modulate the immune system to treat diseases such as allergies or to enhance protection in transplantation and autoimmune disorders. Aditxt is developing a platform that is intended to use a patient's own immune cells to reprogram them so that they can be reintroduced into the patient to fight rejection, infection, and diseases.
Leadership and Structure
Amro Albanna is the CEO. The company has a board of directors responsible for corporate governance.
Top Products and Market Share
Key Offerings
- AditxtScore: AditxtScore is a diagnostic test designed to assess the status of a person's immune system. There is no direct market share data publicly available. Competitors include companies in the immune monitoring space such as Adaptive Biotechnologies, Quanterix, and LabCorp.
- AditxtReprogramming: AditxtReprogramming is a therapeutic technology platform focused on modulating the immune system. There is no market share data available. Competitors include companies developing cell therapies and immunomodulatory drugs, such as Novartis and Kite Pharma (Gilead).
Market Dynamics
Industry Overview
The immune monitoring and modulation market is growing due to increasing prevalence of autoimmune diseases, transplantations, and infectious diseases. Personalized medicine and advanced diagnostics are key drivers.
Positioning
Aditxt aims to be a key player in personalized immune monitoring and modulation. Its competitive advantages include its proprietary technologies for immune profiling and reprogramming.
Total Addressable Market (TAM)
The global immune monitoring market size was valued at USD 4.75 billion in 2023 and is projected to grow at a CAGR of 8.5% from 2024 to 2032. Aditxt aims to capture a significant portion of this TAM with its innovative technologies.
Upturn SWOT Analysis
Strengths
- Proprietary technology platform
- Focus on personalized medicine
- Potential for disruptive innovation
Weaknesses
- Limited financial resources
- Early stage of development
- Dependence on key personnel
Opportunities
- Partnerships with pharmaceutical companies
- Expansion into new therapeutic areas
- Increasing adoption of personalized medicine
Threats
- Competition from established players
- Regulatory hurdles
- Technological obsolescence
Competitors and Market Share
Key Competitors
- ADPT
- QTRX
- LH
Competitive Landscape
Aditxt is a small player compared to established companies. Its advantage lies in its proprietary technology, but it faces challenges in scaling up and competing with larger companies' resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by technological development and strategic partnerships.
Future Projections: Future growth depends on successful clinical trials and commercialization of its products. Analyst estimates vary widely due to the speculative nature of the company's prospects.
Recent Initiatives: Recent initiatives include advancing clinical trials for AditxtScore and AditxtReprogramming, and expanding partnerships.
Summary
Aditxt is an early-stage company with promising technology in personalized immune monitoring and modulation. Its strengths include proprietary technologies and a focus on a growing market. The company's weaknesses include limited financial resources and being in the early stages of the development. Its future success relies on clinical trials, partnerships, and commercialization of its products, which are also risk factors.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. The stock market is volatile, and investment decisions should be based on individual research and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aditxt Inc.
Exchange NASDAQ | Headquaters Mountain View, CA, United States | ||
IPO Launch date 2020-06-30 | Co-Founder, Chairman, CEO & President Mr. Amro A. Albanna | ||
Sector Healthcare | Industry Biotechnology | Full time employees 26 | Website https://www.aditxt.com |
Full time employees 26 | Website https://www.aditxt.com | ||
Aditxt, Inc., a commercial-stage company, discovers and develops products in the areas of immune health, precision health, population health, women's health, and neurologic health. The company develops AditxtScore that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Mountain View, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.